Novartis AG said its new drug for multiple sclerosis will have a wholesale price of about $48,000 a year per person in the U.S., making it among the most expensive drugs for the disease.
The Swiss drug giant is launching the treatment, Gilenya, in the U.S. this month.
via online.wsj.com
1 comment:
If Gilenya’s ingredient (fingolimod) costs $14 a month, why is Novartis wanting $4,000 a month for it? Check it out. Google "buy fingolimod" and you will find several companies that sell fingolimod for non-human research (so more applications can be found). At one company it costs $42.00 for 50mg. The Gilenya website says that the pills would be 0.05mg each day. That's about 15mg a month. Simple math shows that we could all get fingolimod for about $14 a month if we were allowed to buy it that way. Based on their projected price of $4,000 a month, that’s a 285 times markup!
Gilenya is a cheap fungal metabolite that has been used in Chinese herbal medicine. Read the research: The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors9, The Journal of Biological Chemistry, Vol. 277, No. 24, Issue of June 14, pp. 21453-21457, 2002. You'll find it online in pdf form. Novaris is the sponsor of the study at the college.
It is also my opinion that the $4,000 a month was figured by adding a thousand to the average $3,000 a month of the other therapies. They figure that no needles are worth $1,000 a month. The company line is that they are offering co-pay assistance. Of course they are! At $4,000 a month they can give out half-price coupons and still make a hefty profit. Another company line is that insurance will cover most of the cost. With 40% of Americans not insured, I wonder how many people with MS aren’t able to afford any therapy at all. My co-pay for Copaxone WITH my insurance is 25% or $777.10.
As much as I hate needles and as good as the product predicts to be, I suggest we all boycott Novartis’ Gilenya until they lower their price to at least $1,000 a month. That's still exorbitant but they do have the clinical trials and their research to pay for. If half of the people with MS bought it for $1,000 they would recoup their money fast at over $166 million a month (175,000 people X ($1,000 -$50 costs)). Of course, all of the other MS therapy companies would be upset but if all of them have been setting their prices based on what the others are getting, it’s called price fixing. They call it marketing. For us it’s called crippling.
Gilenya is not an expensive biologic like Betaseron. I did use Betaseron and got drug-induced Lupus and had to change to Copaxone. At least Betaseron uses the overies of Guniea pigs (in China) and that requires high manufacturing costs (and yuk!). I can almost see the large manufacturing cost for Betaseron and other biologics but it looks like all of the other therapies base their price on Betaseron’s high price. I think the drug companies are really taking advantage of the fact that there is no cure and they’ve got us over a barrel.
Yes, I'm posting everywhere but y'all do the same and spread the word. Let's show Novartis’ Gilenya that people with MS are tougher and smarter than they think!
Post a Comment